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Differential expression of protein kinase C isoforms in strepto- Hyperglycemia is the major causal factor in the patho-
zotocin-induced diabetic rats. genesis of diabetic vascular complications. An elevated
Background. The cellular effects of hyperglycemia are medi- blood glucose may mediate its adverse effects through
ated by protein kinase C (PKC). However, PKC consists of
multiple pathways [1–5]. Studies in isolated glomeruliseveral distinct isoforms, and their contribution to the patho-
and in cultured endothelial, smooth muscle, and mesan-genesis of diabetic complications in different organs is not
gial cells have demonstrated that high ambient concen-clear. We investigated the expression and translocation of PKC
isoforms a, bI, bII, d, e, and z in kidney, heart, and aorta from trations of glucose activate protein kinase C (PKC) and
diabetic rats. thereby implicate hyperglycemia per se as a mediator of
Methods. Hyperglycemia was induced with streptozotocin PKC activation [2, 6]. Several authors have demonstrated
(70 mg/kg) in the rat. After four weeks, PKC isoform expres-
that both in vitro and in vivo increased glucose concen-sion was assessed by Western blot after tissue fractionation
trations lead to the de novo synthesis of diacyl glyceroland by immunohistochemistry.
(DAG) [7–13]. High glucose concentrations activateResults. Streptozotocin increased blood glucose from 117.0 6
3.6 to 510.0 6 19.4 mg/dl (N 5 8, P , 0.01) and induced PKC by increasing cellular DAG levels, the major media-
albuminuria. PKC isoforms a, b, d, e, and z were all detected tor of this signaling system [14–27]. The activation of
in control animals. Western blot showed increased PKC a PKC regulates various vascular functions by modulating
expression in kidney and heart (160% and 170%, respectively). enzymatic activities such as cytosolic phospholipase A2PKC bI, bII, and d expression was not influenced by hypergly-
and Na1-K1-ATPase, as well as gene expression of extra-cemia. PKC z was decreased in diabetic animals in both tissues
cellular matrix components and contractile proteins [6,by 60%. The membrane association of PKC a and PKC e
28–31]. PKC may thereby be involved in the pathogene-was increased; however, the relative amount of PKC in the
particulate fraction was not influenced by hyperglycemia. Im- sis of both the functional and structural alterations of
munohistochemistry revealed a marked increase in PKC a the kidney in diabetes.
immunoreactivity in renal glomeruli and interstitial capillaries, In vitro, increased extracellular glucose leads to a rapid
cardiac capillaries, and skeletal muscle, as well as in the endo-
PKC activation within minutes, and its activity remainsthelial cells of larger arteries. PKC b showed a small decrease
increased for several days [16, 24, 32]. In vivo, increasedin the glomeruli. PKC e was increased in renal tubules in dia-
PKC activity has been found in glomeruli, heart, andbetic rats but was decreased in the myocardium. PKC z was
expressed in both myocardial and glomerular cells but was retinal vessels within days of streptozotocin-induced hy-
decreased during hyperglycemia. Our results demonstrate that perglycemia [14, 33, 34]. The sustained activation of the
PKC isoforms are differentially regulated in kidney and heart enzyme has been linked to increased DAG generation
in diabetes. High glucose increases PKC a expression, whereas in diabetic tissue [6]. However, activated PKC is inacti-PKC z is down-regulated. The finding that PKC a is mostly
vated by enzymatic cleavage; sustained activation of theincreased in endothelial cells supports a role for PKC a in
enzyme has been generally associated with down-regula-functional endothelial disturbances observed in diabetes.
tion of the protein and loss of PKC activity. A possible
explanation of the sustained increase in PKC activity is
an enhanced expression of the enzyme during hypergly-Key words: diabetes, PKC isoform a, gene transfer, antisense oligo-
nucleotides, hyperglycemia, endothelium, kidney. cemia. In fact, increased PKC expression has been ob-
served in the diabetic kidney [35] and in the retinal circu-Received for publication June 26, 1998
lation [17]. We have previously shown that increasedand in revised form June 14, 1999
Accepted for publication June 17, 1999 PKC expression is associated with an increase in trans-
forming growth factor-b (TGF-b) [36]. 1999 by the International Society of Nephrology
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The PKC issue is further complicated by the fact that egtazic acid (EGTA), 25 mm leupeptin, and 5 mm phenyl-
methylsulfonyl acid (PMSF)] and immediately homo-PKC is not a single entity but consists of several isoforms
with distinct cellular functions and different expression genized. The homogenate was then incubated for one
hour with benzonase (Merck, Darmstadt, Germany) andpatterns [37]. Considerable debate exists about which iso-
form is involved in the glucose-induced activation. Ino- boiled for 10 minutes at 958C. Afterward, it was spun at
1600 g for 15 minutes. The cardiac tissue was homoge-guchi et al observed an increased expression of the PKC
isoform bII in tissue from diabetic animals and hypothe- nized in phosphate-buffered saline (Seromed, Berlin, Ger-
many). Subsequently, boiling lysis buffer was added (1%sized that this PKC isoform is primarily responsible for
the glucose-induced effects in diabetes [34]. Further evi- sodium dodecyl sulfate, 1 mm sodium vanadate, 10 mm
Tris-HCl, pH 7.4), and the samples were microwaved fordence for this hypothesis stems from recent reports that
a specific PKC b inhibitor ameliorates hyperglycemia- 30 seconds. The homogenate was then spun at 12,000 g
for five minutes. After determination of protein content,induced changes in the vasculature [17, 38, 39]. However,
PKC b may not be expressed in all cell types of the the immunoblotting was carried out as previously published
[42]. Briefly, 60 mg of each sample were run on a 10%vascular wall. We were not able to detect PKC b expres-
sion in endothelial cells, even though these cells re- polyacrylamide gel and electroblotted onto a Poly Screen
polyvinylidine difluoride (PVDF) Transfer Membranesponded to changes in extracellular glucose concentra-
tion [40]. In addition, we recently reported that high (NEN, Boston, MA, USA). The membrane was then
treated according to a commercially available protocolglucose increases endothelial cell permeability via PKC a
[41] and that PKC a plays an important role in vascular (Serva, Heidelberg, Germany). The membrane was incu-
bated with antibodies directed against defined epitopessmooth muscle cell (VSMC) differentiation [36]. White-
side et al have recently described an increased membrane of six different PKC isoforms (a, b, d, e, and z; Transduc-
tion Laboratories, Lexington, KY, USA). The antibodyassociation of PKC a, but also of PKC d and e, in a
diabetic rat model [42]. We were therefore especially against PKC b is a polyconal antibody. For the detection
of the two variants PKC bI and PKC bII, we used mono-interested in investigating the expression and transloca-
tion of PKC isoforms in a rat model of diabetes and to clonal antibodies from GIBCO (Eggenstein, Germany).
A final incubation was carried out with peroxidase conju-analyze their cellular distribution in kidney and heart.
gated antimouse IgG (Pierce Chemicals, Oud-Beijerland,
Netherlands). Visualization was achieved by chemilumi-
METHODS
nescence (Renaissance; DuPont, Boston, MA, USA).
Animal protocol
ImmunocytochemistryExperiments were performed in accordance with the
Helsinki Declaration and The Guiding Principles in the Experiments were carried out as described previously
[43]. Frozen renal and cardiac tissues specimens wereCare and Use of Animals. Male Sprague-Dawley rats
(Ivanovas, Kisslegg, Germany) aged eight weeks were cryosectioned at 6 mm thickness and air dried. The sec-
tions were fixed in cold acetone, air dried, and washedmaintained in cages at 24 6 28C. Animals were fed a
standard pellet diet and were allowed free access to wa- in Tris-buffered saline (TBS; 0.05 m Tris-buffer, 0.15 m
NaCl, pH 7.6). The sections were incubated for 60 min-ter. Diabetes was induced by a single intraperitoneal
injection of 70 mg/kg body wt streptozotocin (Sigma utes in a humid chamber at room temperature or over-
night at 48C with primary monoclonal antibodies againstChemical Co., Deisenhofen, Germany). Blood glucose
concentrations were determined 48 hours after strepto- PKC isoforms (discussed earlier in this article). After
washing with TBS, the sections were incubated with azotocin using an automated glucose analyzer (Eppen-
dorf, Hamburg, Germany). Rats with a blood glucose bridging antibody (rabbit-antimouse IgG; Dako, Ham-
burg, Germany) for 30 minutes at room temperature andconcentration above 300 mg/dl during the study period
were declared “diabetic,” whereas age-matched normog- washed again with TBS. The APAAP-complex (alkaline-
phosphatase-antialkaline-phosphatase; Dako) was ap-lycemic animals were used as controls. Body weight, 24-
hour urine protein excretion, and blood glucose concen- plied, and the sections were incubated for 30 minutes at
room temperature. The immunoreactivity was visualizedtrations were determined weekly. Twenty-four–hour al-
bumin excretion was measured using an enzyme-linked by development in a mixture of napthtol-AS-BI-phos-
phate (Sigma) with neufuchsin (Merck). Endogenousimmunosorbent assay technique.
alkaline phosphatase was blocked by addition of 10 mm
Western blotting levamisole (Sigma) to the substrate solution. The sec-
tions were slightly counterstained in Mayer’s hemalaunThe excised organs were divided with forceps and scis-
sors. The renal tissue was treated with cold buffer [50 (Merck), blued in tap water, and mounted with GelTol
(Coulter-Immuotech, Hamburg, Germany). For immu-mm Tris-HCl, pH 7.4, 2% sodium dodecyl sulfate (SDS),
1 mm ethylenediaminetetraacetic acid (EDTA), 10 mm nofluorescence, detection of bound primary antibodies
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was performed with preabsorbtion against rat serum pro- of the glomerular loops and in the adventitia. In hyper-
teins affinipure goat antirabbit IgG (H 1 L) conjugated glycemic animals, the expression of PKC a was greatly
with dichlortriazinyl aminofluorescein (DTAF) at a dilu- enhanced (Fig. 1 B, D, and F). The most prominent
tion of 1:100. For fluorescent microscopy, DTAF-labeled increase was present in the glomeruli and the endothe-
cryosections were mounted with Citifluor (Plano GmbH, lium of larger vessels (Fig. 1 B, D). In addition, tubular
Wetzlar, Germany) with or without nuclear counterstain- PKC immunoreactivity was enhanced, and more immu-
ing with propidium iodide. Preparations were examined noreactive material was present in the vascular lumen
under a Zeiss Axioplan-2 microscope (Zeiss, Jena, Ger- and the adventitia. An increased expression in endothe-
many) and photographed using a color reversal film Agfa lial cells was also seen in the heart (Fig. 1F).
CTX 100. The data shown are representative of at least In Figure 2, the expression of PKC isoforms b (Fig. 2
five independent experiments that gave similar results. A–D) and d (Fig. 2 E–H) are shown. In renal tissue of
The controls were as follows: (a) omission of incubation normoglycemic animals (Fig. 2A), PKC b was present
with primary AB and (b) substitution of primary AB by both in the tubules and glomeruli. A more prominent
the corresponding mouse IgG subclass (Dianova, Ham- expression of PKC b was observed in cardiac myocytes
burg, Germany) at the same final concentration. (Fig. 2C). Hyperglycemia induced a modest decrease of
PKC b immunoreactivity in the glomeruli (Fig. 2B). A
Statistical analysis
decreased PKC b expression was also observed in the
Statistical analysis was carried out with a commercially cardiac myocytes from diabetic animals. In vessels in
available program (SPSS Inc., Chicago, IL, USA). To both the kidney and the heart, a weak, nonsignificant
standardize densitometric values for each Western blot, staining for PKC b was observed. The influence of hyper-
the results from diabetic animals were calculated as the glycemia on PKC b in the vessels was not significant
percentage as compared with control animals. These val- (data not shown). PKC d showed only a faint expression
ues were then tested by univariate t-tests against 100% in normal kidney and heart (Fig. 2 E, G), which was not
under the null hypothesis of no difference. These com- influenced by hyperglycemia.
parisons were carried out for the different PKC isoforms We then used two monoclonal antibodies to investi-
and the different tissues. The results (mean 6 sem) repre- gate the expression of the two PKC b variants. The
sent duplicate measurements made on 7 to 10 separate results for PKC bI are shown in Figure 3 A–D. PKC bI
rats from each group. Nonparametric (Wilcoxon test) was more prominently expressed in tubular cells com-
and parametric (two-way analysis of variance) were used pared with glomeruli. In the heart, a more homogenous
as appropriate. P # 0.05 was considered significant. distribution was observed. PKC bII showed an increased
immunoreactivity in the glomeruli, whereas the staining
pattern in the heart was not different from PKC bI inRESULTS
the heart. Hyperglycemia had no significant effect onInduction of hyperglycemia in the eight-week-old rats
the immunoreactivity of both b isoforms in the kidneyby streptozotocin resulted in an increased blood glucose
(Fig. 3 A, B and E, F), whereas a small increase ofconcentration after one week (356.9 6 20.9 vs. 116.7 6
immunoreactivity for bI was observed in the heart (Fig.8.8 mg/dl, N 5 16, P , 0.01). Hyperglycemia persisted
3 C, D and F, G).in the treated animals and was 510.0 6 19.4 mg/dl at
In Figure 4, the expression of PKC isoforms e (Fig. 4four weeks as compared with 117.0 6 3.6 mg/dl in the
A–D) and z (Fig. 4 E–H) are shown. PKC e was promi-control animals. The hyperglycemic animals developed
nently expressed in the renal tubules and was almostalbuminuria. Twenty-four hour urinary albumin excre-
undetectable in the glomeruli. Hyperglycemia inducedtion in the hyperglycemic animals was 2329 6 1015 mg/
a significant increase in tubular PKC e expression, but24 hr after four weeks, whereas in the control animals,
had little effect in the glomeruli. In contrast to the results343 6 73 mg/24 hr were measured (N 5 16, P , 0.01).
with the other PKC isoforms, PKC e was differentiallyAfter four weeks, the animals were killed, and the organs
influenced by hyperglycemia in the kidney and in thewere assessed for PKC isoform a, bI, bII, d, e, and z
heart. The strong expression of PKC e in cardiac myo-expression. We first investigated the expression of PKC
cytes was reduced during hyperglycemia and showed aisoform a in kidney and heart of diabetic animals. These
patchier pattern. Finally, we examined the expression ofresults are shown in Figure 1. The left panels show immu-
PKC z (Fig. 4 E–H). This isoform was evenly distributednostains of renal (Fig. 1 A, C) and cardiac (Fig. 1E)
in renal tubules and glomeruli (Fig. 4E). In the heart, atissue from normoglycemic control rats. The right panels
strong expression in the cardiomyocytes was observedshow the respective immunostains from diabetic rats.
(Fig. 4G). Hyperglycemia decreased the expression ofPKC a was weakly expressed in the tubules with a pre-
PKC z in the glomeruli and caused a slightly increasedponderance toward the apical surface (Fig. 1 A, C). A
faint expression of PKC a was also visible in focal areas immunoreactivity in the tubules (Fig. 4F). In the heart,
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Fig. 1. Immunohistochemistry of PKC isoform a in kidneys (A–D) and heart (E and F) from normoglycemic (left panels) and hyperglycemic
animals (right panels). In renal tissue from normoglycemic rats, PKC a was faintly expressed in the glomeruli and apical tubules (A). Hyperglycemia
increased PKC a expression in the glomeruli and the interstitial space (B). Hyperglycemia also induced and increased expression in the endothelium
and in the perivascular space (C and D). Similar changes were present in the vessels of the heart (E and F).
a relative decrease of PKC z expression in the myocytes expression in the normoglycemic (control) animals. In
both the kidney and the heart, PKC a was detected aswas observed (Fig. 4H).
After the immunohistochemical analysis of the tissue an isolated band with a molecular weight of 82 kDa.
In diabetic animals, PKC a expression was significantlywas performed, we used Western blot analysis to sub-
stantiate further the influence of hyperglycemia on PKC increased in the kidney and the heart (N 5 8, P , 0.05).
PKC b and its two splicing variants were detected as aisoforms in the kidney and the heart. These results are
shown in Figure 5 for the kidney and in Figure 6 for single band with a molecular weight of 80 kDa. Expres-
sion of PKC b in diabetic animals was not significantlythe heart. Results are expressed in percentage enzyme
Fig. 2. Immunohistochemistry of PKC b (common antibody; A–D) and PKC d (E–H) in kidney (A and B, E and F), and myocardium (C and D,
G and H) of normoglycemic (left panel) and hyperglycemic rats (right panel).
Fig. 3. Immunohistochemistry of PKC bI (A–D) and PKC bII (E–H) in kidney (A and B, E and F), and myocardium (C and D, G and H) of
normoglycemic (left panel) and hyperglycemic rats (right panel).
Fig. 4. Immunohistochemistry of PKC e (A–D) and PKC z (E–H) in kidney (A and B, E and F), and myocardium (C and D, G and H) of
normoglycemic (left panel) and hyperglycemic rats (right panel).
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Fig. 5. Protein expression (A) and translocation (B and C) of PKC isoforms a, bI, bII, d, e, and z in renal tissue of normoglycemic control (c)
and hyperglycemic (gl) rats. For the translocation experiments, renal cortical tissue was fractionated by ultracentrifugation, and the cytosolic and
particulate fractions were analyzed. Bars represent the densitometric analysis of more than experiments. Symbols in C are: ( ) particulate fraction;
( ) cytosolic fraction; (h) control; (j) hyperglycemia.
changed (N 5 8). PKC d in kidney and heart had a chemistry had indicated that the increased PKC a expres-
sion was mostly localized in the endothelium. Therefore,molecular weight of 78 kDa and was also not influenced
by hyperglycemia (N 5 8). PKC e was detected at 90 we next used immunofluorescence to test the hypothesis
that PKC a expression is increased in the endotheliumkDa. As described in the immunohistochemical analysis,
immunoreactivity of this isoform was increased in the of diabetic animals. The results of these experiments are
shown in Figure 7. Tissue from normoglycemic controlkidney but showed a decrease in the heart (N 5 8, P ,
0.05). Finally, PKC z was detected at a molecular weight animals is shown in the left panel, and in tissue from
hyperglycemic animals is shown in the right panel. Hy-of 72 kDa and was less expressed in diabetic animals
both in the kidney and the heart (N 5 8, P , 0.05). perglycemia induced an increase in PKC a immunoreac-
tivity in the kidney, which was mostly localized in theWe then analyzed the influence of hyperglycemia on
the translocation of the PKC isoforms in renal tissue. glomerular and peritubular capillaries (Fig. 7 A–D). Es-
pecially in Figure 7D, the distinct increase in immunore-These results are shown in Figure 5B. We were able to
confirm that the expression of PKC a was increased. The activity of peritubular capillaries is evident. We then
examined skeletal muscle. Figure 7 E and F demonstratetranslocation experiments showed an increased mem-
brane-association of PKC a and PKC e in hyperglycemic that PKC a immunoreactivity was increased in capillaries
of skeletal muscle. Finally, we analyzed the endotheliumanimals; however, the percentage of cytosol versus par-
ticulate remained unaltered by hyperglycemia. of larger blood vessels and demonstrated an increased
PKC a immunoreactivity in the endothelium of the aortaThe Western blot analysis demonstrated an increased
expression of PKC a in diabetic animals. Immunohisto- (Fig. 7 G, H).
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Fig. 6. Western blotting of PKC isoforms a, bI, bII, d, e, and z in myocardial tissue of normal and hyperglycemic rats. Bars are densitometric
analysis of more than experiments. Symbols are: (h) control; (j) hyperglycemia.
DISCUSSION of diabetes-associated organ damage [6]. Our results,
together with earlier observations, suggest that high glu-We investigated PKC isoform expression in the kid-
cose concentrations mainly affect PKC isoform a [41, 45].ney, heart, blood vessels, and skeletal muscle from hyper-
This finding is supported by our recent observation thatglycemic animals. Our most important finding was an in-
the glucose-induced increase in endothelial cell perme-creased PKC a expression during hyperglycemia, whereas
ability is also mediated by PKC a [41]. Glucose-inducedPKC b was not significantly influenced. We demonstrated
activation of this PKC isoform has also been describedthat the increased PKC a expression was localized to
by Ganesan et al [46]. However, another PKC isoform,endothelial cells and especially enhanced in capillaries.
namely PKC bII, has been implicated in the intracellularIn addition, we found that PKC e was increased in tubules
effects of glucose-induced activation of this enzyme fam-of diabetic animals but was decreased in the myocardium
ily. In two rat diabetic models, the PKC bII isoform wasand that PKC z was down-regulated under hyperglyce-
found to be preferentially increased in aorta and heart,mic conditions. These results underscore the importance
whereas PKC a did not change significantly [17, 38].of PKC isoforms in diabetes-induced organ damage and
An increased expression of PKC bII was also recentlysuggest an important role for the PKC isoform a in
reported in cultured VSMCs [18]. Further support for aendothelial function in diabetes.
role of PKC bII in hyperglycemia comes from a studySeveral in vitro studies have previously demonstrated
by Ishii et al, who recently demonstrated that an oralthat the intracellular effects of high glucose concentra-
inhibitor of PKC b ameliorates vascular dysfunction intion are mediated by PKC [23, 32]. Because PKC is an
diabetic rats [39]. However, most of the evidence for aimportant regulatory molecule in several cellular reactions
role of PKC b in glucose-induced cell activation stemsimportant to diabetic complications, such as expression
from experiments using a selective PKC b inhibitor [18].of matrix proteins and metalloproteases, PKC activation
by hyperglycemia may play a role in the pathogenesis Conceivably, the compound used in these studies could
Fig. 7. Immunofluorescence of PKC a in renal tissue (A–D), skeletal muscle (E and F ), and aorta (G and H ) of normoglycemic (left panel) and
hyperglycemic rats (right panel).
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also have inhibited PKC a. Another explanation for the Most of the previous reports on a role of PKC as
the cellular effector of hyperglycemia and diabetes havediscrepant results in these studies and our observations
could be a differential expression of PKC isoforms in focused on the activation of PKC via glucose-generated
diacylglycerol [reviewed in 6]. In contrast, we observeddifferent vascular cell types. Our previous finding, that
high glucose increases permeability via PKC a, was ob- an increase in PKC a expression during hyperglycemia
in the rat. This finding would indicate that a high glucosetained in endothelial cells [41]. We could not detect ex-
pression of PKC b by Western blot and reverse transcrip- concentration not only induces activation of PKC but
also enhances expression of PKC a. Indirect evidencetion-polymerase chain reaction (RT-PCR) in endothelial
cells in an earlier study [40]. It is therefore conceivable for such a mechanisms comes from several studies in
which long-term effects of glucose on PKC activity werethat glucose influences PKC a in cell types in which PKC
b is not present. However, we have previously shown described. Williams and Schrier demonstrated that con-
tinued exposure to d-glucose induced a sustained PKCthat high glucose concentration induces translocation of
both PKC a and b in VSMCs [16]. In the present study, activation for up to 48 hours [32]. In a previous report,
we observed an increased PKC activity up to 72 hours ofwe could not detect an increase in PKC b expression,
but rather a modest decrease in the glomeruli. Although high glucose concentration [16]. Because PKC activation
leads to a rapid down-regulation of the enzyme and itsthis finding does not rule out an increase in PKC b
activity in the diabetic animals, these data support our activity, the sustained activation during hyperglycemia
argues for an increased PKC expression and/or proteinhypothesis that PKC a is an important intracellular medi-
ator of high glucose concentrations. Our observations stabilization. In support for such a hypothesis, several
authors have reported a sustained increase in PKC activ-concerning the role of PKC a are further supported by
the recent observations from Whiteside et al [42]. They ity in diabetes and hyperglycemia. Giles et al have re-
cently shown increased total PKC activity in the heartsdemonstrated a significant increase in membrane-associ-
ated PKC a, d, and e after two and four weeks of hyper- of diabetic animals [51]. Similar findings in the heart
have been obtained by others [22]. However, Cravenglycemia in the rat, whereas PKC b was not influenced.
In contrast to our observations, they found most of the and Derubertis did not find an increase in total PKC
activity, but rather an enhanced enzyme activity only inincreased PKC a immunoreactivity in the membrane
fraction. This discrepancy, however, could be explained the membrane fraction of isolated glomeruli [14]. In or-
der to solve this issue, we are currently cloning the PKCby methodological differences because we have pre-
viously shown that PKC translocation studies in whole a promoter to investigate the regulation of PKC a gene
expression.tissue are difficult, and small changes in the homogeniza-
tion procedure may influence the amount of membrane- We observed an increased PKC e expression in the
kidney of diabetic animals, whereas a decrease was ob-bound enzyme [43]. We have previously shown that in
vascular smooth muscle cells, inhibition of PKC a by served in the heart. The role of PKC e in the kidney is
not well understood. PKC e has been implicated in theantisense oligonucleotides resulted in a decreased ex-
pression of TGF-b, while down-regulation of PKC b signal transduction of proliferation, and both stimulatory
and inhibitory functions have been suggested [52–54]. Ithad no influence [44]. Whiteside et al did not observe a
decrease in PKC z expression [42], whereas Kikkawa et seems that PKC e is linked to raf-1 kinase activation and
the mitogen-activated protein kinase pathway, and a roleal have previously shown that PKC z is translocated by
high glucose in mesangial cells [45]. for this PKC isoform in mechano-sensitive signal trans-
duction and expression of matrix proteins has been sug-The effects of hyperglycemia on PKC in different cell
types may vary. In skeletal muscle from hyperglycemic gested [55–58]. We recently demonstrated that PKC e,
together with PKC a, may play a role in endothelialanimals, a down-regulation of PKC activity was ob-
served, whereas in other tissues, PKC activity was found cell permeability, and the increased expression of both
isoforms could indicate a cooperative effect in diabetes-to be increased [46–50]. Furthermore, Donnelly et al
recently observed a distinct increase of PKC isoform t induced changes of permeability [41]. However, PKC e
was mostly increased in the renal tubules. Several au-in skeletal muscle from diabetic animals [50]. Therefore,
we cannot rule out the possibility that other PKC iso- thors have recently implicated PKC e in salt and water
transport in the nephron and have shown that this iso-forms besides PKC a mediate the effects of high glucose
and hyperglycemia in other cell types and tissues. How- form mediated the effects of vasopressin and angiotensin
II [59, 60]. The decreased expression of PKC e in myocar-ever, in our animal experiments, we observed an increase
in the expression of PKC a. This observation is supported dial tissue is interesting because recently a distinct role
of this PKC isoform in preconditioning was suggestedby a recent report of increased PKC a expression in
myocardial tissue from diabetic animals, suggesting a [61]. A decreased expression during hyperglycemia could
indicate that the protection against ischemia is less pro-role of PKC a in the cellular response to hyperglycemia
in the heart [51]. nounced in diabetes. In addition, PKC e has been impli-
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7. Ayo SH, Radnik R, Garoni JA, Troyer DA, Kreisberg JI: Highcated in stretch-mediated responses in the heart [62].
glucose increases diacylglycerol mass and activates protein kinase
Malhotra et al have suggested that angiotensin II recep- C in mesangial cell cultures. Am J Physiol 261:F571–F577, 1991
8. Chiarugi V, Bruni P, Pasquali F, Magnelli L, Basi G, Ruggierotor-mediated activation of PKC e may play a role in the
M, Farnararo M: Synthesis of diacylglycerol de novo is responsiblecontractile dysfunction seen in chronic diabetes [63].
for permanent activation and down-regulation of protein kinase C
In contrast to PKC isoform e, PKC z was decreased in transformed cells. Biochem Biophys Res Commun 164:816–823,
1989in both myocardium and kidney. Although PKC z has
9. Craven PA, Davidson CM, DeRubertis FR: Increase in diacyl-been characterized in kidney [64] and has been impli-
glycerol mass in isolated glomeruli by glucose from de novo synthe-
cated in mitogenic signaling [65], its function is not clear. sis of glycerolipids. Diabetes 39:667–674, 1990
10. Farese RV, Rosic N, Standaert M, Babischkin J, Cooper DR,PKC z also seems to stimulate the MAP/ERK pathway,
Davis JS, Pollet RJ: Further evidence implicating diacylglycerolhowever, via a different mechanism [66, 67]. Recently,
generation and protein kinase C activation in agonist-induced in-
a role for PKC z was demonstrated in the expression of creases in glucose uptake: Insulin-like effects of phenylephrine in
BC3H-1 myocytes. Diabetes 35:951–957, 1986COX-2, prostaglandin E2 (PGE2), and inducible nitric
11. Ishizuka T, Hoffman J, Cooper DR, Watson JE, Pushkin DB,oxide synthase in mesangial cells [68]. Possibly, the al-
Farese RV: Glucose-induced synthesis of diacylglycerol de novo
tered expression of PKC z in diabetes influences the is associated with translocation (activation) of protein kinase C in
rat adipocytes. FEBS Lett 249:234–238, 1989regulation of these enzymes; however, currently, the po-
12. Okumura K, Akiyama N, Hashimoto H, Ogawa K, Satake T:tential role of PKC z in diabetic nephropathy is unclear.
Alteration of 1,2-diacylglycerol content in myocardium from dia-
In summary, we found that hyperglycemia has a differ- betic rats. Diabetes 37:1168–1172, 1988
13. Wolf BA, Williamson JR, Easom RA, Chang K, Sherman WR,ential and specific effect on PKC isoform expression.
Turk J: Diacylglycerol accumulation and microvascular abnormali-We demonstrated increased PKC a expression both in
ties induced by elevated glucose levels. J Clin Invest 87:31–38, 1991
kidney and heart during diabetes. No changes in PKC 14. Craven PA, DeRubertis FR: Protein kinase C is activated in
glomeruli from streptozotocin diabetic rats: Possible mediation byb and d were observed. PKC e showed a differential
glucose. J Clin Invest 83:1667–1675, 1989response to hyperglycemia, with an increase in the kid-
15. Garcia Paramio P, Carmena MJ, Gutierrez Ocana MT, Recio
ney and a decrease in the diabetic heart. PKC z was MN, Prieto JC: Alteration of protein kinase C activity in diabetic
rat prostate. Biochem Biophys Res Commun 195:166–172, 1993decreased in both tissues. Immunohistochemistry re-
16. Haller H, Baur E, Quass P, Behrend M, Lindschau C, Distlervealed that PKC z was decreased in the glomeruli and
A, Luft FC: High glucose concentrations and protein kinase C
in cardiomyocytes. PKC a was most prominently ex- isoforms in vascular smooth muscle cells. Kidney Int 47:1057–1067,
1995pressed in endothelial cells in kidney and heart, but also
17. Ishii H, Koya D, King GL: Protein kinase C activation and its rolein skeletal muscle and larger vessels. In view of our
in the development of vascular complications in diabetes mellitus. J
recent observations on the role of PKC a in endothelial Mol Med 76:21–31, 1998
18. Kunisaki M, Bursell SE, Umeda F, Nawata H, King GL: Nor-and VSMCs [36, 41], we suggest a role for PKC a in the
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